Veit J. Erpenbeck

3.6k citations

41 papers · 1.7k indexed · h-index 21

Physiology top 2%
Immunology top 5%
Immunology and Allergy top 1%
Pulmonary and Respiratory Medicine top 10%
Rheumatology top 5%

Co-authors: Norbert Krug Jens M. Hohlfeld Armin Braun Thomas Tschernig Jörg Köhl Janice Canvin Stephen T. Holgate William W. Busse
Topics: Asthma and respiratory diseases (25 papers)Allergic Rhinitis and Sensitization (16 papers)IL-33, ST2, and ILC Pathways (9 papers)
Cited by: Immunology and Allergy Physiology Immunology
Journals: The Journal of Experimental Medicine The Journal of Immunology PLoS ONE
Partner nations: Switzerland Germany United States

In The Last Decade

Veit J. Erpenbeck

39 papers receiving 1.6k citations

Peers

Countries citing papers authored by Veit J. Erpenbeck

Since Specialization

Citations

This map shows the geographic impact of Veit J. Erpenbeck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veit J. Erpenbeck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veit J. Erpenbeck more than expected).

Fields of papers citing papers by Veit J. Erpenbeck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Veit J. Erpenbeck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veit J. Erpenbeck. The network helps show where Veit J. Erpenbeck may publish in the future.

Co-authorship network of co-authors of Veit J. Erpenbeck

This figure shows the co-authorship network connecting the top 25 collaborators of Veit J. Erpenbeck. A scholar is included among the top collaborators of Veit J. Erpenbeck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Veit J. Erpenbeck. Veit J. Erpenbeck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Roles of Type 2 Cytotoxic T Cells in Inflammation, Tissue Remodeling, and Prostaglandin (PG) D2 Production Are Attenuated by PGD2 Receptor 2 Antagonism 2021 ·The Journal of Immunology ·Wentao Chen,Jian Luo,(unknown),(unknown),Wei Liu,(unknown),Shamsah Kazani,Eric A. Shikatani,Veit J. Erpenbeck,Ian Pavord,Paul Klenerman,David A. Sandham,Luzheng Xue	11
2	Prostaglandin D2 metabolites activate asthmatic patient-derived type 2 innate lymphoid cells and eosinophils via the DP2 receptor 2021 ·Respiratory Research ·(unknown),(unknown),Veit J. Erpenbeck,Shamsah Kazani,Jens M. Hohlfeld,David A. Sandham,Meike Müller	8
3	Increased type 2 inflammation post rhinovirus infection in patients with moderate asthma 2019 ·Cytokine ·Thomas Southworth,(unknown),Naimat Ullah Khan,(unknown),Robert M. Strieter,Veit J. Erpenbeck,Dave Singh	25
4	Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double‐blind, placebo‐controlled study 2018 ·Allergy ·Martin Metz,Rebecca I. Torene,Sérgio Kaiser,Michael T. Beste,Petra Staubach,Andrea Bauer,Randolf Brehler,Janine Gericke,Martin Letzkus,Nicole Hartmann,Veit J. Erpenbeck,Marcus Maurer	26
5	U-BIOPRED: evaluation of the value of a public–private partnership to industry 2018 ·Drug Discovery Today ·John Riley,Veit J. Erpenbeck,John G. Matthews,Cécile Holweg,Christopher Compton,Wolfgang Seibold,T. W. Higenbottam,Scott Wagers,Anthony Rowe,David Myles	11
6	Safety, tolerability and pharmacokinetics of QAV680, an oral CRTh2 antagonist, in healthy subjects 2014 ·European Respiratory Journal ·Veit J. Erpenbeck,Rainard Fuhr,Gerald Dubois,(unknown)	0
7	Efficacy and safety of 10 day treatment with the CRTh2 antagonist QAV680 evaluated in patients with allergic rhinitis in an environmental exposure chamber 2014 ·European Respiratory Journal ·Veit J. Erpenbeck,(unknown),Piyush M. Patel,(unknown),Gerald Dubois,Ping Zhou,(unknown),Michael Larbig	3
8	QAV680, cetirizine and their combination reduce nasal symptoms in patients with intermittent allergic rhinitis in an environmental exposure chamber 2014 ·European Respiratory Journal ·Veit J. Erpenbeck,Anne Marie Salapatek,Piyush M. Patel,(unknown),Gerald Dubois,(unknown),Michael Larbig	2
9	Safety, tolerability and pharmacokinetics of an oral competitive reversible CRTh2 antagonist, QAW039, in healthy subjects 2014 ·European Respiratory Journal ·Veit J. Erpenbeck,Eva Vets,Lien Gheyle,(unknown),Michael Larbig,(unknown),Gerald Dubois,(unknown)	3
10	Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table 2014 ·Pulmonary Pharmacology & Therapeutics ·Oliver Kornmann,Henrik Watz,Rainard Fuhr,Norbert Krug,Veit J. Erpenbeck,(unknown)	27
11	Surfactant Protein D modulates allergen particle uptake and inflammatory response in a human epithelial airway model 2012 ·Respiratory Research ·Carsten Schleh,Barbara Rothen‐Rutishauser,Fabian Blank,(unknown),Matthias Nassimi,Norbert Krug,Armin Braun,Veit J. Erpenbeck,Peter Gehr,Jens M. Hohlfeld	18
12	Allergen particle binding by human primary bronchial epithelial cells is modulated by surfactant protein D 2010 ·Respiratory Research ·Carsten Schleh,Veit J. Erpenbeck,Carla Winkler,(unknown),Matthias Nassimi,Armin Braun,Norbert Krug,Jens M. Hohlfeld	12
13	Pharmacological Targeting of Anaphylatoxin Receptors during the Effector Phase of Allergic Asthma Suppresses Airway Hyperresponsiveness and Airway Inflammation 2005 ·The Journal of Immunology ·(unknown),Barbara Fuchs,Wilfried Bautsch,(unknown),Jörg Köhl,Heinz G. Hoymann,Thomas Glaab,Veit J. Erpenbeck,Norbert Krug,Armin Braun	90
14	Local nitric oxide levels reflect the degree of allergic airway inflammation after segmental allergen challenge in asthmatics 2005 ·Nitric Oxide ·Veit J. Erpenbeck,Rudolf A. Jörres,(unknown),Harald Krentel,Dimitrios Tsikas,Birgit Luettig,Norbert Krug,Jens M. Hohlfeld	12
15	Increased Expression of Interleukin-9 Messenger RNA After Segmental Allergen Challenge in Allergic Asthmatics 2003 ·CHEST Journal ·Veit J. Erpenbeck,Jens M. Hohlfeld,(unknown),Harald Krentel,(unknown),Armin Braun,Norbert Krug	29
16	Increased Messenger RNA Expression of c-maf and GATA-3 After Segmental Allergen Challenge in Allergic Asthmatics 2003 ·CHEST Journal ·Veit J. Erpenbeck,Jens M. Hohlfeld,(unknown),Harald Krentel,(unknown),Armin Braun,Norbert Krug	16
17	Segmental allergen challenge in patients with atopic asthma leads to increased IL-9 expression in bronchoalveolar lavage fluid lymphocytes 2003 ·Journal of Allergy and Clinical Immunology ·Veit J. Erpenbeck,Jens M. Hohlfeld,(unknown),(unknown),Henning Geldmacher,Armin Braun,Norbert Krug	121
18	Divergence in urinary 8-iso-PGF2α (iPF2α-III, 15-F2t-IsoP) levels from gas chromatography–tandem mass spectrometry quantification after thin-layer chromatography and immunoaffinity column chromatography reveals heterogeneity of 8-iso-PGF2α 2003 ·Journal of Chromatography B ·Dimitrios Tsikas,Edzard Schwedhelm,(unknown),(unknown),Frank‐Mathias Gutzki,Veit J. Erpenbeck,Jens M. Hohlfeld,Andrzej Surdacki,Jürgen C. Frölich	78
19	Complement Factors C3a and C5a are Increased in Bronchoalveolar Lavage Fluid after Segmental Allergen Provocation in Subjects with Asthma 2001 ·American Journal of Respiratory and Critical Care Medicine ·Norbert Krug,Thomas Tschernig,Veit J. Erpenbeck,Jens M. Hohlfeld,Jörg Köhl	150
20	Interleukin 16 and T-cell Chemoattractant Activity in Bronchoalveolar Lavage 24 Hours after Allergen Challenge in Asthma 2000 ·American Journal of Respiratory and Critical Care Medicine ·Norbert Krug,William W. Cruikshank,Thomas Tschernig,Veit J. Erpenbeck,(unknown),Jens M. Hohlfeld,H Fabel	31

About Veit J. Erpenbeck

Veit J. Erpenbeck is a scholar working on Immunology and Allergy, Physiology and Immunology, having authored 41 papers that have together received 1.7k indexed citations. Recurring topics across this work include Asthma and respiratory diseases (25 papers), Allergic Rhinitis and Sensitization (16 papers) and IL-33, ST2, and ILC Pathways (9 papers). The work is most often cited by research in Immunology and Allergy (429 citations), Physiology (858 citations) and Immunology (589 citations). Veit J. Erpenbeck has collaborated with scholars based in Switzerland, Germany and United States. Frequent co-authors include Norbert Krug, Jens M. Hohlfeld, Armin Braun, Thomas Tschernig, Jörg Köhl, Janice Canvin, Stephen T. Holgate, William W. Busse, Nicola A. Hanania and Philip J. Lowe. Their work appears in journals such as The Journal of Experimental Medicine, The Journal of Immunology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact